J&J adds cancer warning to diabetic foot gel

WASHINGTON (Reuters) - Johnson & Johnson has added a strong "black box" warning about the risk of cancer in patients treated with the company's Regranex diabetic foot gel, U.S. regulators said on Friday.

A study showed the risk of dying from cancer was five times higher for patients who used three or more tubes of Regranex when compared with others who did not use the product, the Food and Drug Administration said.

(Reporting by Lisa Richwine; editing by John Wallace)